At present, no previous studies have related the levels of this enzyme with adenosine signaling in diabetic nephropathy, but it is suggested that the use of the ADORA3 antagonist could have a major role on caspase 1 activation, which is a necessary event in the generation of interleukins. Here, CASP1 is linked to diabetic kidney disease.